Resistance to immune checkpoint therapy in ccRCC can additionally be attributed to failed reversal or reinvigoration of dysfunctional M2-like TAMs and exhausted CD8+ T cells, as has been suggested in other cancers (42–45, 56, 57, 67–71). This evidence concerns the gene CD8A and nonpapillary renal cell carcinoma.